Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction

• Published in: International journal of ophthalmology 2018-04, Vol.11 (4), p.593-600
• Main Authors: Kim, Ho-Yun, Lee, Ji-Eun, Oh, Ha-Na, Song, Ju-Whan, Han, Sang-Youp, Lee, Jong-Soo
• Format: Article
• Language: English
• Subjects: 0.05% cyclosporine; 0.1% hyauronate; Clinical Research; dry eye; meibomian gland dysfunction
• ISSN: 2222-3959; 2227-4898
• DOI: 10.18240/ijo.2018.04.09

To investigate the efficacy of combined topical 0.05% cyclosporine A (CsA; Restasis , Allergan pharmaceuticals, USA) and 0.1% sodium hyaluronate treatment in dry eyes with meibomian gland dysfunction (MGD). In a retrospective analysis, 53 patients (106 eyes) with MGD were enrolled and performed lid warm massage for 10min daily and be instilled preservative free sodium hyaluronate 0.1% eye drops 4 times daily. Patients were divided into subjects treated with topical 0.05% CsA and preservative free sodium hyaluronate vehicle (experimental group, =74 eyes) and subjects treated with the preservative free sodium hyaluronate vehicle (control group, =32 eyes). They were evaluated at baseline and 1, 2, and 3mo for subjective symptoms and objective signs including tear film break-up time (tBUT), Schirmer test, corneal staining (CS) score, lid margin telangiectasia (LMT), meibomian gland secretion (MGS), and conjunctival injection (CI). In the short-term treatment, the experimental group showed a statistically significant improvement in the ocular surface disease index (OSDI;